Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 5/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20958537 | 1.00 | CHRM2 (0.44) | CHRM2CHRM1CHRM3LMNACYP2C9 | |
| SCHEMBL20958534 | 1.00 | CHRM2 (0.44) | CHRM2CHRM1CHRM3LMNACYP2C9 | |
| SCHEMBL1165401 | 1.00 | CHRM2 (0.44) | CHRM2CHRM1CHRM3LMNACYP2C9 | |
| SCHEMBL639674 | 0.91 | CHRM2 (0.52) | CHRM2CHRM1CHRM3LMNACYP2C9 | |
| SCHEMBL19307797 | 0.91 | CHRM2 (0.52) | CHRM2CHRM1CHRM3LMNACYP2C9 | |
| SCHEMBL17062522 | 0.91 | CHRM2 (0.52) | CHRM2CHRM1CHRM3LMNACYP2C9 | |
| SCHEMBL1164966 | 0.91 | CHRM2 (0.52) | CHRM2CHRM1CHRM3LMNACYP2C9 | |
| SCHEMBL19617523 | 0.91 | CHRM2 (0.52) | CHRM2CHRM1CHRM3LMNACYP2C9 | |
| SCHEMBL1164859 | 0.91 | CHRM2 (0.52) | CHRM2CHRM1CHRM3LMNACYP2C9 | |
| SCHEMBL19617896 | 0.91 | CHRM2 (0.52) | CHRM2CHRM1CHRM3LMNACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665733-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | Bristol-Myers Squibb Company (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2024173323-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-22 | — | — | WO | disclosed |
| US-11319312-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED | 2022-05-03 | — | — | US | disclosed |
| EP-3810607-A1 | OXADIAZOLES AS AGONISTS OF THE MUSCARINIC M1 AND/OR M4 RECEPTOR | Heptares Therapeutics Limited (GB) | 2021-04-28 | — | — | EP | disclosed |
| US-20210101893-A1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2021-04-08 | — | — | US | disclosed |
| US-10858352-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-12-08 | — | — | US | disclosed |
| WO-2019243850-A1 | OXADIAZOLES AS AGONISTS OF THE MUSCARINIC M1 AND/OR M4 RECEPTOR | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-12-26 | — | — | WO | disclosed |
| WO-2011021645-A1 | BICYCLIC UREA DERIVATIVE OR PHARMACOLOGICALLY PERMITTED SALT THEREOF | 大日本住友製薬株式会社 (JP) | 2011-02-24 | — | — | WO | disclosed |
| EP-1934212-A1 | 9-AZABICYCLO [3 . 3 . 1]NONANE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS | N.V. Organon (NL) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007039563-A1 | 9-AZABICYCLO [3 . 3 . 1] NONANE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS | N.V. ORGANON (NL) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319312-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | CHRM2 2/4885CHRM1 1/4885CHRM3 4/4885 |
| US-10858352-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | CHRM2 2/4885CHRM1 1/4885CHRM3 4/4885 |
| US-20210101893-A1 | PHARMACEUTICAL COMPOUNDS | CHRM1, CHRM2, CHRM4 | CHRM2 2/4885CHRM1 1/4885CHRM3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.